Trial
NCT04375527
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
Array BioPharma; Bristol-Myers Squibb
Condition
Clinical Stage III Cutaneous Melanoma AJCC V8
Intervention
Binimetinib
Why stopped
poor enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-04